These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29067643)

  • 1. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
    Wainberg ZA; Alsina M; Soares HP; Braña I; Britten CD; Del Conte G; Ezeh P; Houk B; Kern KA; Leong S; Pathan N; Pierce KJ; Siu LL; Vermette J; Tabernero J
    Target Oncol; 2017 Dec; 12(6):775-785. PubMed ID: 29067643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
    Del Campo JM; Birrer M; Davis C; Fujiwara K; Gollerkeri A; Gore M; Houk B; Lau S; Poveda A; González-Martín A; Muller C; Muro K; Pierce K; Suzuki M; Vermette J; Oza A
    Gynecol Oncol; 2016 Jul; 142(1):62-69. PubMed ID: 27103175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
    Shapiro GI; Bell-McGuinn KM; Molina JR; Bendell J; Spicer J; Kwak EL; Pandya SS; Millham R; Borzillo G; Pierce KJ; Han L; Houk BE; Gallo JD; Alsina M; Braña I; Tabernero J
    Clin Cancer Res; 2015 Apr; 21(8):1888-95. PubMed ID: 25652454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
    Curigliano G; Shapiro GI; Kristeleit RS; Abdul Razak AR; Leong S; Alsina M; Giordano A; Gelmon KA; Stringer-Reasor E; Vaishampayan UN; Middleton M; Olszanski AJ; Rugo HS; Kern KA; Pathan N; Perea R; Pierce KJ; Mutka SC; Wainberg ZA
    Br J Cancer; 2023 Jan; 128(1):30-41. PubMed ID: 36335217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
    Simmons BH; Lee JH; Lalwani K; Giddabasappa A; Snider BA; Wong A; Lappin PB; Eswaraka J; Kan JL; Christensen JG; Shojaei F
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):213-20. PubMed ID: 22684718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
    Colombo I; Genta S; Martorana F; Guidi M; Frattini M; Samartzis EP; Brandt S; Gaggetta S; Moser L; Pascale M; Terrot T; Sessa C; Stathis A
    Clin Cancer Res; 2021 Sep; 27(18):5012-5019. PubMed ID: 34266890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
    Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
    Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
    Pitts TM; Newton TP; Bradshaw-Pierce EL; Addison R; Arcaroli JJ; Klauck PJ; Bagby SM; Hyatt SL; Purkey A; Tentler JJ; Tan AC; Messersmith WA; Eckhardt SG; Leong S
    PLoS One; 2014; 9(11):e113037. PubMed ID: 25401499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
    Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
    Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
    Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
    Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
    Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells.
    Murase Y; Hosoya K; Sato T; Kim S; Okumura M
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35088890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
    Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
    Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
    Britten CD; Adjei AA; Millham R; Houk BE; Borzillo G; Pierce K; Wainberg ZA; LoRusso PM
    Invest New Drugs; 2014 Jun; 32(3):510-7. PubMed ID: 24395457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
    Radovich M; Solzak JP; Wang CJ; Hancock BA; Badve S; Althouse SK; Bray SM; Storniolo AMV; Ballinger TJ; Schneider BP; Miller KD
    Clin Cancer Res; 2022 Aug; 28(15):3235-3241. PubMed ID: 35551360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.